Invitae is engaged in the business of delivering genetic testing services, digital health solutions and health data services that support a lifetime of patient care from inherited disease diagnoses, to family planning, to proactive health screening to personalized diagnosis, treatment and monitoring of cancer. Testing and other services are delivered via a platform that serves patients, healthcare providers, biopharma companies and other partners. Co. applies proprietary design, process automation, robotics and bioinformatics software solutions to achieve efficiencies in sample processing and complex variant interpretation, allowing medical interpretation at scale. The NVTA stock yearly return is shown above.
The yearly return on the NVTA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NVTA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|